Trump administration advances ibogaine, other experimental mental health treatments

The Department of Health and Human Services is working to advance research into psychedelic and other rapid-acting psychiatric drugs as potential treatments for mental health and substance use disorders through two initiatives announced Thursday.

The department will invest up to $4.9 million over five years to advance the powerful psychoactive drug ibogaine as a potential treatment for post-traumatic stress disorder, particularly among veterans.

The initial awards, administered through the Advanced Research Projects Agency for Health, will support the regulatory, clinical and manufacturing groundwork needed to pursue future clinical trials, rather than fund human clinical trials or patient treatment.

Veterans organizations have been among the most vocal proponents of expanding access to ibogaine, arguing that it could offer an alternative to conventional treatments that have failed some patients.

“Veterans have told us ibogaine changed their lives. Their experiences demand serious scientific investigation,” Kennedy said.

Separately, the National Institute of Mental Health opened a $20 million funding opportunity to establish a research network studying rapid-acting psychiatric treatments, including psilocybin, ketamine and esketamine. Funding recipients are expected to be announced in summer 2027.

The initiatives are part of a broader effort by the administration to accelerate research into psychedelic treatments for serious mental illnesses and substance use disorders.

In April, President Donald Trump signed an executive order directing federal agencies to expedite research and regulatory reviews of experimental psychedelic treatments, including ibogaine, and allocate at least $50 million in existing funding to support state psychedelic research initiatives.

Americans for Ibogaine, an organization founded in 2025 that advocates for developing ibogaine into an FDA-approved medication, called Thursday’s announcement a “huge step forward.”

Its CEO, Bryan Hubbard, previously led efforts in Kentucky to use opioid settlement funds to support the drug’s development as a treatment for addiction.

Hubbard said Thursday’s announcement represents unusually rapid progress toward the medicalization of ibogaine.

Keep reading

Unknown's avatar

Author: HP McLovincraft

Seeker of rabbit holes. Pessimist. Libertine. Contrarian. Your huckleberry. Possibly true tales of sanity-blasting horror also known as abject reality. Prepare yourself. Veteran of a thousand psychic wars. I have seen the fnords. Deplatformed on Tumblr and Twitter.

Leave a Reply